OPRM1 and respiratory depression: Subsequent pharmacokinetic/pharmacodynamic modeling studies suggest that buprenorphine at sufficiently high plasma concentrations prevents binding of potent opioids to the MOR, causing less respiratory depression and other opioid-related unwanted effects, including opioid craving (8, 9).